I wish Acadia would get their A into G and start the ball rolling to offer NNZ2591 to Retts and Fragile-X sufferers. Perhaps they are waiting for more success with Neurens current trials for NNZ2591, but surely it makes sense being the "superior" drug with little or no side-effects.... watch this space... Daybue II is coming.
I wish Acadia would get their A into G and start the ball...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
0.000(0.00%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 66 | $19.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.35 | 193 | 1 |
View Market Depth
| Last trade - 09.47am 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.39 |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.41 | $19.39 | 198 | ||
| Last updated 10.07am 14/06/2024 ? | |||||
| NEU (ASX) Chart |
Day chart unavailable